Replies to post #132110 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Market Populations Not Clinical Trials People

helping 1/5 of the population is conservative because 2-73 could still beat SOC in a non selected population

Yes, only a portion of the Australian Alzheimer’s patients in the Anavex 2-73 Phase 1 / 2 clinical trial had really super outcomes; better, more normalized thinking. For those folks, nothing could be better.

But what about the others, where Anavex 2-73 “merely” held cognition at the levels at the start?

Many are implying or contending that Anavex 2-73 will simply be a not-very-effective new Alzheimer’s drug, effectively treating only a portion of the many who have or will get the disease.

But, once again, thinkers on the issue must understand things in the new Phase 3 clinical trial, and especially, when in clinical use by physicians, will not reflect in any way the Australian study results. Here’s how things will be so favorably different.

One of the biggest findings of the dissection of the Australian trial data sets was the discovery that, simply, earlier administration of the drug, before more severe symptoms set in elevates, increases the drug’s efficacy. Sooner is better.

Once approved by the FDA, no physician, no drug label warnings, will restrict the use of the drug only in people in mid- to mild-level stages of Alzheimer’s. By no means. Just the opposite.

Existing clinical data show that the earlier the drug is administered against Alzheimer’s, the better its benefits. Therefore, success percentages (reversals of cognition declines) will be much higher.

It’s not known yet, of course. But with early, first-symptoms dosing of Anavex 2-73 against Alzheimer’s, might efficacy approach 100%?

[attilathehunt]

Can you provide link to your claims please.